This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ExPEC Vaccine
Description: The glycoconjugate ExPEC (Extra-intestinal Pathogenic Escherichia coli) vaccine was produced using GlycoVaxyn's proprietary biological conjugation platform and contains surface polysaccharide antigens of the most predominant ExPEC strains.
GlycoVaxyn and Janssen
In January 2014, GlycoVaxyn announced that Janssen signed an exclusive license agreement and entered a three-year research and development collaboration to develop a multi-valent bacterial vaccine employing GlycoVaxyns bio-conjugation technology.
GSK and GlycoVaxyn
In December 2012, GlycoVaxyn announced a collaboration with GlaxoSmithKline (GSK) to develop new bacterial vaccines employing GlycoVaxyns bio-conjugation technology.The agreement includes an undisclosed set of pathogen targets in the field of bacterial vaccines. GSK retains an option to obtain an exclusive license on these targets during the three-year term of the collaboration and to extend both the term as well as scope of the collaboration. GlycoVaxyn receives an upfront payment and an equity investment. In addition, GlycoVaxyn is eligible to receive milestone payments and royalties on licensed vaccine candidates. Financial terms have not been disclosed.
In...See full deal structure in Biomedtracker
ExPEC Vaccine News
Additional information available to subscribers only: